Pro Medicus (ASX: PME) Signs A$128 Million New York Hospital Deal
Pro Medicus will deploy its full Visage 7 imaging platform across NYC Health + Hospitals under a 10-year, A$128 million transaction-based contract.
20 Nov 2026, 10:34 am · 2 min read
There are 165 ASX-listed companies in the Health Care sector.
Pro Medicus will deploy its full Visage 7 imaging platform across NYC Health + Hospitals under a 10-year, A$128 million transaction-based contract.
20 Nov 2026, 10:34 am · 2 min read
Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial missed its primary endpoint across the overall population. The company will conserve cash and examine a stronger result in patients older than 75.
19 Nov 2026, 11:35 am · 3 min read
Lumos Diagnostics is adding FebriDx to another 97 WellStreet urgent care clinics, expanding adoption to 141 locations. Financial terms and expected test volumes were not disclosed.
09 Nov 2026, 11:06 am · 2 min read
Orthocell’s strategic partner Marine Biomedical has secured U.S. FDA clearance for PearlBone. Orthocell owns 12% of the company and holds a first right of refusal over global distribution rights.
03 Nov 2026, 10:05 am · 2 min read
Clever Culture Systems has completed and invoiced three APAS sales in Q1 FY27. Its advancing pharmaceutical pipeline underpins a target of eight sales and new evaluations for the first half.
28 Oct 2026, 11:05 am · 2 min read
Clarity Pharmaceuticals has dosed the planned 383 participants in its registrational Phase III CLARIFY trial. Topline results are expected in the first half of 2027.
27 Oct 2026, 10:42 am · 2 min read
Lumos Diagnostics has expanded FebriDx to 265 live US healthcare sites, with another 485 under evaluation. Product revenue accelerated, but cash burn and slower paediatric study recruitment remain key considerations.
27 Oct 2026, 10:14 am · 2 min read
Invex Therapeutics will acquire Rekover in an all-scrip deal and raise $10 million, adding the Phase 2a REVIVE multiple sclerosis study to its portfolio.
26 Oct 2026, 10:15 am · 2 min read
Patrys has advanced intravenous delirium candidate RLS-2202 into Cohort 2 after an acceptable initial safety review. The next cohort will compare its pharmacokinetics with oral quetiapine.
22 Oct 2026, 10:32 am · 2 min read
The first 100 patients have completed two years of blinded treatment in Dimerix’s ACTION3 Phase 3 trial. Of those participants, 93 entered the open-label extension study.
16 Oct 2026, 10:25 am · 2 min read
Syntara’s SNT-4728 produced a statistically significant difference in clinician-assessed motor signs 12 weeks after treatment ended. The exploratory result adds to earlier evidence of reduced brain inflammation.
07 Oct 2026, 10:18 am · 2 min read
dorsaVi has secured A$3 million to expand its human movement data capabilities for humanoid robotics and progress its RRAM validation chip program.
06 Oct 2026, 10:14 am · 2 min read
Artrya has secured its largest US deployment to date through a five-year agreement with Huntsville Hospital Health System. The contract has a US$500,000 minimum value, with additional fee-per-scan revenue possible.
02 Oct 2026, 10:18 am · 2 min read
Vectus Biosystems has secured an FDA pre-IND meeting for lead fibrosis candidate VB0004. Written guidance expected by mid-November 2026 will inform the program’s next steps.
30 Sept 2026, 10:14 am · 2 min read
Neuren Pharmaceuticals expects US patent protection for trofinetide to extend by almost five years to March 2041 following allowance of a weight-banded dosing patent application.
29 Sept 2026, 10:10 am · 2 min read
30-day announcements
| Rank | ASX code | Company | 30-day announcements |
|---|---|---|---|
| 1 | NOX | NOXOPHARM LIMITED | 23 |
| 2 | NUZ | NEURIZON THERAPEUTICS LIMITED | 23 |
| 3 | CSL | CSL LIMITED | 18 |
| 4 | CYP | CYNATA THERAPEUTICS LIMITED | 17 |
| 5 | NAN | NANOSONICS LIMITED | 17 |
Bold Investors provides factual news coverage of ASX company announcements. Nothing on this page is financial advice. Articles are grounded in the company's own announcements.